Get to know our clinical trials
Clinical trial of sacituzumab govitecan as first line treatment in patients with metastatic or advanced non-small cell lung cancer (NSCLC) without clinically useful genomic alterations.
PRIMARY OBJECTIVE: - TO EVALUATE THE OBJECTIVE RESPONSE RATE (ORR) OF SACITUZUMAB GOVITECAN (SG) IN COMBINATION WITH PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS A PLATINUM DERIVATIVE. - DETERMINE THE RECOMMENDED PHASE II DOSE (DRF2) OF SG IN COMBINATION WITH PEMBROLIZUMAB PLUS A PLATINUM DERIVATIVE.
Technical Summary
- PHASE II, MULTICENTER, OPEN-LABEL, OPEN-LABEL STUDY OF SACITUZUMAB-GOVITECAN COMBINATIONS AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC OR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITHOUT CLINICALLY USEFUL GENOMIC ALTERATIONS. IMMUNOTHERAPY
- Code EudraCT: 2021-004280-27
- Protocol number: GS-US-576-6220
- Promoter: Gilead Science
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.